🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07234565
Recruiting Not applicable

SOCIAL_HF: Improving Social Frailty Through Interactive Learning

NCT07234565 · tracked via the Priya Life Science China tracker
Sponsor
The University of Hong Kong
Phase
Not applicable
Started
2025-09-15
Last updated
2025-11-18

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

SOCIAL_HFSelf-study heart failure self-care manual

SOCIAL_HF: Participants will engage in a 6-week, WeChat-based group learning program called SOCIAL\_HF, focused on heart failure self-care. This program comprises two key components: structured real-time interactive learning and ongoing synchronous support. Real-time interactive learning will be conducted through WeChat video group meetings weekly, featuring peer sharing, problem-solving collaborative tasks, health goal setting, progress sharing, and the establishment of group contracts. Daily synchronous chat interactions will revolve around completing group contract tasks, weekly quizzes, and daily sharing. Additionally, participants will have access to an online self-care resource hub on the WeChat platform for reference and use.

Self-study heart failure self-care manual: The control group will establish a WeChat connection with PI and receive standard care, which includes a health education manual. However, they will not participate in group learning or discussions. They can consult with research assistants via WeChat for any questions they may have, but the researchers will only provide explanations related to the health education manual and will not offer additional educational resources or group interactions.

Study summary

The goal of this clinical trial is to learn whether the WeChat-based program "Social Optimization Chat for Interactive Learning for Heart Failure" (SOCIAL\_HF) can improve social frailty in elderly patients with heart failure. The main questions it aims to answer are:

Can a 6-week WeChat online group interactive learning program (SOCIAL\_HF) improve social frailty? Does the intervention enhance self-care abilities, social participation, and perceived social support? Researchers will compare SOCIAL\_HF to usual care (self-study heart failure self-care manual) to assess whether SOCIAL\_HF can improve social functioning.

Participants will:

Engage in weekly WeChat video meetings for six weeks (Participate in peer sharing and collaborative tasks).

Complete daily health task check-ins. Access online self-care resources.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. 60 years old and above; 2. Live in the community; 3. a definitive diagnosis of heart failure based on the Framingham Heart Failure Diagnostic Criteria; 4. a diagnosis of heart failure for 6 months or longer; 5. evidence of social pre-frailty or frailty, determined by the SFS-8 score ≥ 2; (6) possession of a smartphone and experience using WeChat; (7) be able to read and write Chinese. Exclusion Criteria: 1. severe cognitive impairment or dementia; 2. known mental illnesses; 3. any communication barriers may hinder participation in SOCIAL\_HF, such as illiteracy, reading disabilities, speak local dialect only, and difficulties in language comprehension; 4. any sensory impairments that may affect learning or interaction with others on WeChat, including untreated severe hearing loss and vision impairments; 5. are currently participating in other intervention studies.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Fudan University Affiliated Huadong Hospital Shanghai China Not Yet Recruiting
Shanghai Baoshan District Integrated Traditional Chinese and Western Medicine Hospital Shanghai China Not Yet Recruiting
Shanghai Jiao Tong University School of Medicine Affiliated Songjiang Hospital Shanghai China Recruiting

More The University of Hong Kong trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07234565 on ClinicalTrials.gov ↗ ← All trials in China